Core Laboratories Q2 2024 Adj EPS $0.22 Beats $0.21 Estimate, Sales $130.577M Miss $132.170M Estimate
Portfolio Pulse from Benzinga Newsdesk
Core Laboratories (NYSE:CLB) reported Q2 2024 adjusted EPS of $0.22, beating the estimate of $0.21. However, sales of $130.577M missed the estimate of $132.170M.
July 24, 2024 | 9:17 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Core Laboratories reported Q2 2024 adjusted EPS of $0.22, beating the estimate of $0.21. However, sales of $130.577M missed the estimate of $132.170M.
While Core Laboratories beat EPS estimates, the miss on sales could create mixed sentiment among investors. The slight beat on EPS may provide some support, but the sales miss could limit significant upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100